|
Clearance gained for cobas Cdiff Test
July 2015
EDIT CONNECT
SHARING OPTIONS:
PLEASANTON, Calif.—The U.S. Food and Drug Administration has
granted 510(k) clearance for Roche's cobas Cdiff Test to detect Clostridium difficile
(C. difficile) in stool samples. The test targets the toxin B gene found in toxigenic C. difficile strains directly in specimens from
symptomatic patients, and demonstrated excellent performance in a clinical trial program, offering high assay sensitivity and rapid turnaround time.
“With the addition of the cobas Cdiff Test to the cobas 4800 System menu, Roche is able to expand the tools available
to assist clinicians in the management of healthcare associated infections," said Paul Brown, head of Roche Molecular Diagnostics. “The cobas
Cdiff Test requires less sample handling and provides laboratories with a simplified workflow when compared to other molecular methods. It also delivers a
lower inhibition rate, which means fewer repeat samples and chances for error, enabling better patient care.”
Code: Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|